Estrella Immunopharma, Inc. ESLA PHARMA
Company Overview
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
Why Investors Should Care
Generates a return on equity of 126.0%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 126.0%.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -24.67% |
| 6 Months: | -42.83% |
| 3 Months: | -43.34% |
| 1 Month: | -11.44% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)31.18 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 126.0%.
- Healthy ROCE of 126.0%.
CONS
- Trading 79.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ESLA Estrella Immunopharma, Inc. PHARMA | 0.64 | -2.56 | $27.84M | 0.00% | 126.01% | 126.02% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -819 | -3.56K | -108.11K | -144.94K | -423.76K | -2.89M | -2.76M | -2.74M | -169.24K | -1.87M | -1.02M | -469.53K | -3.95M | -3.38M | -2.10M | -5.54M | -4.80M | -2.29M |
| Net Income | -819 | -3.56K | -107.55K | -141.25K | -359.59K | -2.89M | -2.76M | -2.74M | -76.00K | -1.87M | -1.02M | -469.53K | -3.95M | -3.38M | -2.10M | -5.54M | -4.80M | -2.29M |
| Diluted EPS | 0.00 | 0.00 | -0.99 | -0.02 | -0.06 | -34.33 | -16.33 | -8.13 | - | -1.78 | -0.03 | -0.01 | -0.11 | -0.09 | -0.06 | -0.15 | -0.13 | -0.05 |
| R&D Expense | - | - | - | - | - | 2.61M | 2.61M | 2.62M | - | 483.47K | 75.46K | 25.00K | 3.52M | 2.83M | 1.41M | 4.66M | 4.15M | 1.40M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Jun 2023 | Jun 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Income | -249.15K | -1.57M | -11.11M | -7.31M | -13.06M |
| Net Income | -247.72K | -996.10K | -11.11M | -7.31M | -13.06M |
| Diluted EPS | - | - | -36.35 | -0.27 | -0.35 |
| R&D Expense | - | - | 10.45M | 4.11M | 10.25M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2021 | Dec 2021 | Jun 2022 | Dec 2022 | Jun 2023 | Jun 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 45.80M | - | 9.72M | 3.03M | 4.45M | 3.14M | 3.18M |
| Total Equity | 0 | -1.01M | -1.04M | -2.26M | -11.74M | 4.27M | 143.73K | -10.37M |
| Cash & Equivalents | - | 478.87K | - | 40.80K | 2.48M | 4.17M | 916.92K | 1.38M |
| Total Liabilities | - | 1.62M | - | 2.65M | 9.77M | 180.70K | 3.00M | 13.54M |
| Current Liabilities | - | 73.15K | - | 1.07M | 9.76M | 180.70K | 3.00M | 13.54M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Jun 2023 | Jun 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -316.16K | -1.04M | -1.34M | -16.07M | -1.79M |
| Investing Cash Flow | -45.19M | 36.17M | -273.07K | 4.96M | - |
| Financing Cash Flow | 45.98M | -35.56M | - | 12.79M | 2.25M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Jun 2023 | Jun 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | 24.6% | 44.2% | 94.7% | -171.1% | 126.0% |
| ROCE % | -0.5% | -18.1% | 165.2% | -171.1% | 126.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Armistice Capital, LLC | 9.14% | 3.98M | $2.10M |
| 2 | Vanguard Capital Management LLC | 0.96% | 416.85K | $220.51K |
| 3 | Geode Capital Management, LLC | 0.32% | 141.32K | $74.76K |
| 4 | Vanguard Fiduciary Trust Co | 0.15% | 64.92K | $34.34K |
| 5 | Blackrock Inc. | 0.12% | 52.03K | $27.52K |
| 6 | State Street Corporation | 0.10% | 43.25K | $22.88K |
| 7 | Renaissance Technologies, LLC | 0.09% | 39.10K | $20.68K |
| 8 | Northern Trust Corporation | 0.08% | 34.86K | $18.44K |
| 9 | US BANCORP \DE\ | 0.05% | 20.00K | $10.58K |
| 10 | Tower Research Capital LLC (TRC) | 0.01% | 3.31K | $1.75K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ESLA
Fantastic News for Tesla Stock Investors! - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxQTTBUaUFlM3VoaG0zV2dYUVAzLTFHMDVsNFItalh0WXk4M2FiNWhQcU9kR2tnVnBhcnVjMXU2NmlkQ1VUUG1MMVlUcjZaT2tYN0cyMER3WDRmZ2JKUTJ0bklWQ2VhclkxTXFFT3kteElyU0dKRGtIS0hRRk05Z1BSTnJCM1lWb2VSRmVr?o…
Is Tesla Stock Under $360 a Share an Obvious Buy in September? - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNc0ZBdXZQQnhpQ1ZLSmk2amZIaEJycDV4dVI4NXhqR0xfZUg0VUJuQnFJRDB3SUN4aE9BZW5xRk1aVzFCem5VSjhoMjFNeVBsZ2lrZ3l5MUNySXJSMWJaYmJtaVdaZXY5V3R2VkxXbzExcE40U1ZwWldfSUVzRUVTeTBfSU5iNUhEQi1heX…
Bill Ackman Drives a Tesla: Here's Why He Won't Buy the Stock - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOMXRidXl1NC1JMlVHWWdmcXhDZFBOM1UyNGNwZGdCbmtJYmxaNE9CYVcxRnZfdi1JR0pyMHZoWWNEaTcwdldyOWt1OWw2ejZyYUgwVE5GQV9LMVNKcHVIYmRnV1JEWjRBU1R6XzJKR0hGUGkwNE9vcXFvMGV0cDZMUjVvVS1SNjh5T3ZwQV…
Tesla shares poised for biggest earnings move in a year - CNBC
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPM0pOYm11WDFobnctTlBLck1ySjFsa3dldFVaVHktS2stTmp5djlDbXltQWRJeEZHMVVxZ0dxM0tRbGtDV3pORWpQQWIySlBjZE1ZdFFnck53M095QjV4M0YzbXd4VEQ5RW9oLS1kenFaczdSRmk4dl9XRVo2WEU0aWpMTlFYQWZHSjU5Vz…
Tesla's Stock Just Bounced Back in a Big Way. Here's Where Traders See It Going Next - Investopedia
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxNN0lqZVR6cFh2aFEtX2VUcl9hS1hlbnNsZmJPMlV2bVFsaGJpYmRYUnJreldMdmo4VHpFZkRLRzVRY25pQzZ6aHdSWGd2aFNlZ1RfYVNZM1NNMDB0UU9XV3RwTlA0ZHhSQkVRZTNwTnJjd1lHSDNqYmtaenFaLUdGYVR1cVZwZkk1eFlFZV…
Estrella Immunopharma (ESLA): Armistice Capital discloses 4.99% ownership stake - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNeENBeXA5cnM2SkJxTDA4NHZKTWEyZjBwODRESmphR05NclFmOTBPVU1vWDZtU2JvQUp2RVl0c0ZKOWw4TlZHRmx3VXcwVDZvVGR5Nno5TkMxc3RtUjQwYzJ3eXdfLU1Wb0Mybk5leXJpWU4yRXlpcVNhWHZzXzdoZGZ5bW80Qjk3Sl9TdG…
ESLA — Frequently Asked Questions
What is the current share price of Estrella Immunopharma, Inc. (ESLA)?
As of 2026-09-19 21:16 PDT, Estrella Immunopharma, Inc. (ESLA) trades at $0.64 on NasdaqCM. Its 52-week range is $0.64 to $3.05.
What is the market capitalisation of ESLA?
Estrella Immunopharma, Inc. (ESLA) has a market capitalisation of $27.84M on NasdaqCM.
What is the P/E ratio of ESLA?
ESLA trades at a trailing price-to-earnings (P/E) ratio of -2.56. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -3.69.
What is the return on equity (ROE) of ESLA?
ESLA has a return on equity (ROE) of 126.02%. Its return on capital employed (ROCE) is 126.01%.
Is ESLA a good stock to buy?
This page provides a data-driven analysis of Estrella Immunopharma, Inc. (ESLA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.